» Articles » PMID: 22098947

Accuracy of B-GGT Fraction for the Diagnosis of Non-alcoholic Fatty Liver Disease

Overview
Journal Liver Int
Specialty Gastroenterology
Date 2011 Nov 22
PMID 22098947
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Serum gamma-glutamyltransferase (GGT) activity is a sensitive but non-specific marker of non-alcoholic fatty liver disease (NAFLD). Recently, four GGT fractions (big-, medium-, small-, free-GGT) were described in humans.

Aim: We aimed to investigate whether a specific GGT fraction pattern is associated with NAFLD.

Methods: Gamma-glutamyltransferase fractions were determined in patients with NAFLD (n = 90), and compared with those in control subjects (n = 70), and chronic hepatitis C (CHC, n = 45) age and gender matched.

Results: Total GGT was elevated in NAFLD as compared to controls (median, 25°-75° percentile: 39.4, 20.0-82.0 U/L vs. 18.4, 13.2-24.9 U/L respectively, P < 0.001). All fractions were higher in NAFLD than in controls (P < 0.001). The b-GGT showed the highest diagnostic accuracy for NAFLD diagnosis [area under ROC curve (ROC-AUC): 0.85; cut-off 2.6 U/L, sensitivity 74%, specificity 81%]. Also subjects with CHC showed increased GGT (41.5, 21.9-84.5 U/L, P < 0.001 vs. controls, P = n.s. vs. NAFLD), as well as m-, s-, and f-GGT, while b-GGT did not show any significant increase (P = n.s. vs. HS, P < 0.001 vs. NAFLD). In subjects with CHC, s-GGT showed the best diagnostic value (ROC-AUC: 0.853; cut-off 14.1 U/L, sensitivity 73%, specificity 90%). Serum GGT did not show any value in the differential diagnosis between NAFLD and CHC (ROC-AUC 0.507, P = n.s.), while b-GGT/s-GGT ratio showed the highest diagnostic accuracy for distinguishing NAFLD and CHC (ROC-AUC: 0.93; cut-off value 0.16, sensitivity 82%, specificity 90%).

Conclusions: b-GGT increases in NAFLD, but not in CHC. GGT fraction analysis might help in improving the sensitivity and specificity of the diagnosis of NAFLD and other liver dysfunctions.

Citing Articles

Extracellular vesicles and glycans: new avenue for biomarker research.

Jankovic T, Jankovic M Biochem Med (Zagreb). 2024; 34(2):020503.

PMID: 38882582 PMC: 11177654. DOI: 10.11613/BM.2024.020503.


Thoughts on Non-Alcoholic Fatty Liver Disease and Chronic Disease.

Pizzorno J, Pizzorno L Integr Med (Encinitas). 2023; 22(2):6-9.

PMID: 37363148 PMC: 10289108.


Development and application of a novel model to predict the risk of non-alcoholic fatty liver disease among lean pre-diabetics with normal blood lipid levels.

Zhu W, Shi P, Fu J, Liang A, Zheng T, Wu X Lipids Health Dis. 2022; 21(1):149.

PMID: 36585668 PMC: 9804963. DOI: 10.1186/s12944-022-01752-5.


Health associations of liver enzymes and inflammatory scores with urinary citrus flavonoid metabolites.

Bullon-Vela V, Xu Y, Razquin C, Abete I, Zulet M, Martinez-Gonzalez M Food Funct. 2022; 14(2):1011-1023.

PMID: 36562455 PMC: 9870039. DOI: 10.1039/d2fo02846h.


The Diagnostic Value of GGT-Based Biochemical Indicators for Choledocholithiasis with Negative Imaging Results of Magnetic Resonance Cholangiopancreatography.

Lin H, Zhou X, Zhang Z Contrast Media Mol Imaging. 2022; 2022:7737610.

PMID: 35949700 PMC: 9348969. DOI: 10.1155/2022/7737610.